Achieve Life Sciences, Inc. (NASDAQ:ACHV) today announced positive top line results from a Phase II clinical trial for nicotine e-cigarettes.  The company also announced positive top line results from its first-ever randomized placebo-controlled trial for nicotine e-cigarettes.  According to the company's press release announcing the results of the trial, which was conducted in the U.S. and Canada, cytisinicline was very well tolerated with 50.9% of subjects who received cytisinicline reporting adverse events compared to 54.7% of subjects in the placebo arm. Adverse events were as expected, mainly mild to moderate, and there were no serious adverse events reported during the study.  The company's Board of Directors has agreed to the entry of a final judgment that permanently enjoins it from violating the antifraud provisions of Section 17(a) of the Securities Act of 1933 ("Securities Act") and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder.  The settlement is subject to court approval.  The SEC's investigation, which is continuing, has been conducted by Helen Bencich, Dr. Cindy Samanthas, and Mr. Abigail Wan of the Chicago Regional Office.  The litigation will be led by Helen Bencich.  The SEC appreciates the assistance of the U.S. Attorney's Office for the District of Illinois, the Federal Bureau of Investigation, and the Financial Industry Regulatory Authority.